Two University of Queensland (UQ) researchers are leading biopharmaceutical associated with more global leader in the development of new peptide-based drugs to treat serious diseases. Peptides are small proteins that can be targeted to specific sites in the body, reducing the risk of side effects. But when taken by mouth, digestive enzymes break down conventional peptides, which means it must be injected to be effective.
The project aims to develop new drugs that build bridges between existing orally bioavailable small molecules and biotherapeutics injection in providing a new generation of orally active treatments for diabetes and cardiovascular disease. Professors David Fairlie and David Craik from the Institute for Molecular Bioscience, UQ (IMB) has received $ 2.5 million from the Australian Research Council (ARC) to work with Pfizer to develop a new generation of drugs that will help overcome the limitations of current treatments.
“We are engineering new types of molecules based on peptides and proteins that are stable enough to be taken orally, yet sufficiently large to be target-specific and help lessen the side effects seen with small molecules,” Professor Craik said. “This project will provide a fundamental understanding for the development of new classes of medicines with the potential to treat a range of diseases,” Professor Fairlie said.
Pfizer is committed to advancing discovery and harnessing innovative science through partnerships. In addition to partnering closely with the IMB to discover and co-develop order valtrex usa next generation medicines, Pfizer will also contribute $2.4 million in funding to the collaboration over the next three years. Dr Dan Grant, Pfizer’s Head of External Research & Development Innovation (Australia, New Zealand and Singapore) said peptide research is one of the most promising fields in the development of the new medicines. The collaboration with IMB supports Pfizer’s Cardiovascular Metabolic Diseases Research Unit (CVMED).
“The development of peptide-based medicines promises to treat diseases that are not currently treatable or well managed with available medicines, such as diabetes. Our CVMED unit is focused on supporting and treating patients with diabetes and the discovery of these innovative therapies may dramatically improve the quality of life for hundreds of thousands of Australian diabetes sufferers,” Dr Grant said.
The partnership combines important scientific souls to a world-class expertise in the latest in science, in hopes of creating a forum to understand the serious diseases that bring new medicines to patients faster and help meet the unmet medical need. Brad Edwards, Senior Vice President, Pfizer Australia Care Unit for Special Affairs, said: “Pfizer is pleased to be partnering with the University of Queensland Institute of Molecular Biosciences, our researchers to identify the strengths that exist in IMB, in particular, that the professors, and Fairlie Craik is the world’s leading chemical peptides and peptides.-drug design. “